Brief: Biocept’s CNside Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations In Patients With Breast Cancer That Has Metastasized To The Brain
09/12/2021 13:18
Dec 9 (Reuters) - Biocept Inc BIOC.O :
* BIOCEPT’S CNSIDE CEREBROSPINAL FLUID ASSAY IDENTIFIES
ACTIONABLE
HER2 MUTATIONS IN PATIENTS WITH BREAST CANCER THAT HAS
METASTASIZED TO THE BRAIN
Source text for Eikon: ID:nBwbr74Bha
Further company coverage: BIOC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork